RESUMEN
This study was designed to assess dialysis subjects' perceived autonomy support association with phosphate binder medication adherence, race and gender. A multi-site cross-sectional study was conducted among 377 dialysis subjects. The Health Care Climate (HCC) Questionnaire assessed subjects' perception of their providers' autonomy support for phosphate binder use, and adherence was assessed by the self-reported Morisky Medication Adherence Scale. Serum phosphorus was obtained from the medical record. Regression models were used to examine independent factors of medication adherence, serum phosphorus, and differences by race and gender. Non-white HCC scores were consistently lower compared with white subjects' scores. No differences were observed by gender. Reported phosphate binder adherence was associated with HCC score, and also with phosphorus control. No significant association was found between HCC score and serum phosphorus. Autonomy support, especially in non-white end stage renal disease subjects, may be an appropriate target for culturally informed strategies to optimize mineral bone health.
Asunto(s)
Personal de Salud/psicología , Hiperfosfatemia/psicología , Fallo Renal Crónico/psicología , Cumplimiento de la Medicación/psicología , Grupos Minoritarios/psicología , Estudios Transversales , Femenino , Humanos , Hiperfosfatemia/sangre , Hiperfosfatemia/complicaciones , Hiperfosfatemia/tratamiento farmacológico , Fallo Renal Crónico/sangre , Fallo Renal Crónico/complicaciones , Masculino , Persona de Mediana Edad , Fósforo/sangre , Autoinforme , Factores SexualesRESUMEN
BACKGROUND: Hyperphosphataemia is linked to cardiovascular disease and mortality in chronic kidney disease (CKD). Outcome in CKD is also affected by socioeconomic status. The objective of this study was to assess the associations between serum phosphate, multiple deprivation and outcome in CKD patients. METHODS: All adult patients currently not on renal replacement therapy (RRT), with first time attendance to the renal outpatient clinics in the Glasgow area between July 2010 and June 2014, were included in this prospective study. Area socioeconomic status was assessed as quintiles of the Scottish Index of Multiple Deprivation (SIMD). Outcomes were all-cause and cardiovascular mortality and commencement of RRT. RESULTS: The cohort included 2950 patients with a median (interquartile range) age 67.6 (53.6-76.9) years. Median (interquartile range) eGFR was 38.1 (26.3-63.5) ml/min/1.73 m(2), mean (± standard deviation) phosphate was 1.13 (± 0.24) mmol/L and 31.6 % belonged to the most deprived quintile (SIMD quintile I). During follow-up 375 patients died and 98 commenced RRT. Phosphate ≥ 1.50 mmol/L was associated with all-cause (hazard ratio (HR) 2.51; 95 % confidence interval (CI) 1.63-3.89) and cardiovascular (HR 5.05; 95 % CI 1.90-13.46) mortality when compared to phosphate 0.90-1.09 mmol/L in multivariable analyses. SIMD quintile I was independently associated with all-cause mortality. Phosphate did not weaken the association between deprivation index and mortality, and there was no interaction between phosphate and SIMD quintiles. Neither phosphate nor SIMD predicted commencement of RRT. CONCLUSIONS: Multiple deprivation and serum phosphate were strong, independent predictors of all-cause mortality in CKD and showed no interaction. Phosphate also predicted cardiovascular mortality. The results suggest that phosphate lowering should be pursued regardless of socioeconomic status.
Asunto(s)
Hiperfosfatemia/diagnóstico , Hiperfosfatemia/mortalidad , Fosfatos/sangre , Insuficiencia Renal Crónica/mortalidad , Insuficiencia Renal Crónica/psicología , Aislamiento Social/psicología , Anciano , Biomarcadores/sangre , Estudios de Cohortes , Comorbilidad , Femenino , Humanos , Hiperfosfatemia/psicología , Incidencia , Masculino , Persona de Mediana Edad , Insuficiencia Renal Crónica/sangre , Reproducibilidad de los Resultados , Medición de Riesgo/métodos , Escocia/epidemiología , Sensibilidad y Especificidad , Análisis de SupervivenciaRESUMEN
OBJECTIVES: Patients with end-stage kidney disease receiving haemodialysis (HD) are at risk of cardiovascular disease and bone disorders related to high levels of serum phosphate. We studied the association between medication beliefs and depressive symptoms, with non-adherence to phosphate binding medication in a group of HD patients at risk of complications due to hyperphosphatemia. DESIGN: Cross-sectional design. METHODS: Baseline data from 112 patients participating in a randomized controlled trial, evaluating an adherence intervention, are presented. All patients had serum phosphate levels >1.6 mmol/l at baseline. Adherence was measured by (1) serum phosphate and (2) Medication Adherence Report Scales (MARS). Beliefs about Medicines (BMQ) and depressive symptoms (PHQ-9) were also evaluated. RESULTS: Beliefs about Medicines Questionnaire necessity, but not concerns, beliefs were found to correlate with serum phosphate (r = -.23, p < .05) and self-reported adherence (r = .35, p < .01). In regression models, controlling for demographic, clinical and psychological variables, necessity beliefs explained the variance of serum phosphate (ß = -.22, p = .01) and self-reported adherence (ß = .30, p ≤ .01). Both BMQ concerns and depressive symptoms were not related to non-adherence. CONCLUSION: Patients' beliefs about the necessity of their prescribed phosphate binding medications explain variation in non-adherence levels, measured both subjective and objectively. Dialysis patient's medication beliefs are potentially modifiable targets for future interventions.
Asunto(s)
Actitud Frente a la Salud , Quelantes/uso terapéutico , Depresión/psicología , Hiperfosfatemia/tratamiento farmacológico , Fallo Renal Crónico/terapia , Cumplimiento de la Medicación/psicología , Diálisis Renal , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Hiperfosfatemia/psicología , Masculino , Persona de Mediana Edad , Encuestas y CuestionariosRESUMEN
BACKGROUND: Hemodialysis patients are at risk of serious health complications, yet treatment non-adherence remains high. PURPOSE: Warnings about health risks associated with non-adherence may trigger defensive reactions. We studied whether an intervention based on self-affirmation theory (Steele 1988) reduced patients' resistance to health-risk information and improved adherence. METHODS: One hundred twelve patients either self-affirmed or completed a matched control task before reading about the risks associated with a lack of phosphate control. Serum phosphate was collected from baseline up to 12 months. RESULTS: Self-affirmed patients had significantly reduced serum phosphate levels at 1 and 12 months. However, contrary to the predictions derived from self-affirmation theory, self-affirmed participants and controls did not differ in their evaluation of the health-risk information, behavioural intention or self-efficacy. CONCLUSIONS: A low-cost, high-reach health intervention based on self-affirmation theory was shown to reduce serum phosphate over a 12 month period. Further work is required to identify mediators of the observed effects.
Asunto(s)
Hiperfosfatemia/prevención & control , Cooperación del Paciente/psicología , Diálisis Renal/psicología , Autoimagen , Femenino , Conductas Relacionadas con la Salud , Humanos , Hiperfosfatemia/etiología , Hiperfosfatemia/psicología , Fallo Renal Crónico/psicología , Fallo Renal Crónico/terapia , Masculino , Cumplimiento de la Medicación/psicología , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Cooperación del Paciente/estadística & datos numéricos , Educación del Paciente como Asunto/métodos , Fosfatos/sangre , Proyectos Piloto , Diálisis Renal/efectos adversosRESUMEN
UNLABELLED: Fahr's syndrome is characterized by the presence of intracerebral, bilateral and symmetrical non-arteriosclerotic calcifications, located in the central grey nuclei. One of its main etiologies is pseudohypoparathyroidism (PHP), due to a resistance to the action of parathormone (PTH) with essentially hypocalcaemia and a normal or a high rate of PTH. CASE REPORT: Mr B.A. is a 36-year-old man, admitted to hospital because of refractory psychotic symptoms associated with alcohol abuse and fits of convulsion, for diagnostic and therapeutic update. Mr B.A. had presented convulsions since the age of 10, without regular medical treatment. He showed a decrease in his school performances and started using alcohol. Since the age of 17, he began expressing delusions of persecution and of enchantment fed by the persistence of the convulsions. He was administered phenobarbital, and classic antipsychotics (haloperidol and levomepromazine) and developed serious extrapyramidal side effects, treated with an anticholinergic (trihexyphenidyl). Evolution was rather disadvantageous: more epileptic fits, exaggeration of tremors; abuse of alcohol and persistence of psychotic symptoms. On admission, psychiatric examination objectified paranoid delusions of being possessed and persecuted by others. Neurological examination revealed the presence of limb tremors, with a positive Froment's sign on the right, and dysarthria. Other than this, the patient was shorter in comparison with his siblings and exhibited bad dentition. A CT brain scan found bilateral, symmetric basal ganglia calcifications, confirmed by MRI, in favour of Fahr's syndrome. Phosphocalcic investigations revealed a low concentration of serum calcium (65 mg/l) and a hyperphosphataemia (60.1mg/l). The blood level of parathyroid hormone was in the upper limit of normal (66 ng/l), and levels of thyroid hormones and thyroid-stimulating hormone were normal. The diagnosis of Fahr's syndrome, revealing a pseudohypoparathyroidism was posed, and the patient was orientated to endocrinology after readjustment in his therapy (sodium valproate and olanzapine). DISCUSSION: About 40% of the patients with Fahr's syndrome are seen with primarily cognitive and other psychiatric findings. For this patient, hypocalcaemia was at the origin of his convulsions, and the use of phenobarbital, known for its hypocalcemiant action, provoked the inverse result. Alcohol drinking also aggravated hypocalcaemia, and maintained the fits. The use of classic antipsychotics and anticholinergic agents, amplified the extrapyramidal signs caused by Fahr's syndrome. Recognizing the origin of the symptoms allowed rethinking the therapeutic strategy according to all these elements. CONCLUSION: Psychiatrists should consider Fahr's syndrome as a differential diagnosis in the evaluation of psychosis associated with convulsions. This case, along with others in the literature, further emphasizes the importance of the role of neuro-imaging and the search for disrupted phosphocalcic metabolism in patients with atypical or refractory psychotic symptoms.
Asunto(s)
Trastornos Paranoides/diagnóstico , Seudohipoparatiroidismo/diagnóstico , Seudohipoparatiroidismo/psicología , Adulto , Alcoholismo/sangre , Alcoholismo/diagnóstico , Alcoholismo/psicología , Ganglios Basales/patología , Enfermedades de los Ganglios Basales/sangre , Enfermedades de los Ganglios Basales/diagnóstico , Enfermedades de los Ganglios Basales/psicología , Calcinosis/sangre , Calcinosis/diagnóstico , Calcinosis/psicología , Calcio/sangre , Comorbilidad , Diagnóstico Diferencial , Humanos , Hiperfosfatemia/sangre , Hiperfosfatemia/diagnóstico , Hiperfosfatemia/psicología , Imagen por Resonancia Magnética , Masculino , Marruecos , Examen Neurológico/estadística & datos numéricos , Trastornos Paranoides/sangre , Trastornos Paranoides/psicología , Hormona Paratiroidea/sangre , Seudohipoparatiroidismo/sangre , Psicometría , Convulsiones/sangre , Convulsiones/diagnóstico , Convulsiones/psicología , Síndrome , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND AND OBJECTIVES: Dialysis patients have a high burden of co-existing diseases, poor health-related quality of life (HR-QOL), and are prescribed many medications. There are no data on daily pill burden and its relationship to HR-QOL and adherence to therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two hundred and thirty-three prevalent, chronic dialysis patients from three units in different geographic areas in the United States underwent a single, cross-sectional assessment of total daily pill burden and that from phosphate binders. HR-QOL, adherence to phosphate binders, and serum phosphorus levels were the three main outcome measures studied. RESULTS: The median daily pill burden was 19; in one-quarter of subjects, it exceeded 25 pills/d. Higher pill burden was independently associated with lower physical component summary scale scores on HR-QOL on both univariate and multivariate analyses. Phosphate binders accounted for about one-half of the daily pill burden; 62% of the participants were nonadherent. There was a modest relationship between pill burden from phosphate binders and adherence and serum phosphorus levels; these associations persisted on multivariate analyses. There was no relationship between adherence and serum phosphorus levels. CONCLUSIONS: The daily pill burden in dialysis patients is one of the highest reported to date in any chronic disease state. Higher pill burden is associated with lower HR-QOL. There are many reasons for uncontrolled serum phosphorus levels; increasing the number of prescribed pills does not seem to improve control and may come at the cost of poorer HR-QOL.
Asunto(s)
Hiperfosfatemia/tratamiento farmacológico , Hiperfosfatemia/psicología , Fallo Renal Crónico/psicología , Cumplimiento de la Medicación/psicología , Calidad de Vida , Diálisis Renal/psicología , Adulto , Anciano , Estudios de Cohortes , Comorbilidad , Costo de Enfermedad , Estudios Transversales , Femenino , Humanos , Hiperfosfatemia/epidemiología , Fallo Renal Crónico/epidemiología , Fallo Renal Crónico/terapia , Masculino , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Análisis Multivariante , Fósforo/sangre , Valor Predictivo de las Pruebas , Prevalencia , Sensibilidad y EspecificidadAsunto(s)
Dietética/métodos , Hiperfosfatemia/dietoterapia , Hiperfosfatemia/etiología , Fallo Renal Crónico/complicaciones , Nefrología/métodos , Selección de Paciente , Actitud Frente a la Salud , Grupos Focales , Humanos , Hiperfosfatemia/psicología , Evaluación de Necesidades , Educación del Paciente como Asunto , Fósforo Dietético/efectos adversos , Factores de TiempoRESUMEN
Information about treatment and its potential side effects has been identified as a core information need amongst Chronic Kidney Disease (CKD) patients. Developing effective interventions to meet patients' information needs requires a better understanding of the specific types of needs from the patients' perspective. Phosphate binding medication (PBM) is an integral component of the treatment regimen for dialysis dependent CKD stage 5 (CKD 5) patients. The aim of this study was to explore patient satisfaction with information received about PBM. Two hundred and twenty-one CKD 5 patients completed the Satisfaction with Information about Medicines Scale (SIMS); a validated measure of patients' satisfaction with various aspects of information provision. The findings suggest that CKD 5 patients may have outstanding PBM information needs, particularly relating to the potential problems associated with PBM. This study justifies further work to identify and address information needs amongst CKD 5 patients.